How it works – Learn more about Laser Ablation in Neurosurgery

In September last year, the CLS laser ablation system for neurosurgical procedures was cleared by the FDA. Since then, development has progressed rapidly. CLS´s partner and global distributor ClearPoint Neuro is now commercializing the system under the brand ClearPoint™ Prism Neuro Laser Therapy System in the US market, a study is ongoing at Skåne University Hospital in Sweden, and recently the hospital published a memo in which the advantages of operating on patients with certain types of brain tumors inside the MRI scanner were clearly highlighted.

But how does it actually work? Welcome to learn more about laser ablation in neurosurgery in the attached pdf.

For more information, please contact:

Liselotte Nilsson, VP Marketing, Clinical Laserthermia Systems AB

E-mail: lotta.nilsson@clinicallaser.com

Phone: +46 - (0)703-736443

Clinical Laserthermia Systems AB (publ) develops and sells the TRANBERG® |Thermal Therapy System, including Thermoguide Workstation and sterile disposables, for minimally invasive treatment of cancer tumors and drug-resistant epilepsy, according to regulatory approvals in the EU and the US. The products are marketed for image-guided laser ablation and for treatment with imILT®, the Company's interstitial laser thermotherapy with potential immunostimulatory effects. CLS is headquartered in Lund and has subsidiaries in Germany, the US and Singapore. CLS is listed on the Nasdaq First North Growth Market under the symbol CLS B. The Certified Advisor (CA) is FNCA Sweden AB, Tel: +46 8 528 00 399. E-mail: info@fnca.se. 

For more information about CLS, please visit the Company's website: www.clinicallaser.se